Russian firm seeks to produce COVID-19 drug remdesivir without patent
By Reuters Staff
MOSCOW (Reuters) – Russian drugmaker Pharmasyntez has asked the Kremlin to allow it to produce a generic version of U.S. COVID-19 drug remdesivir, used to treat U.S. President Donald Trump, despite lacking a patent to do so, the firm’s director said on Monday.
According to medical studies there are ingredients in ED medications that help the muscles coating the blood cialis prescription prices vessels in the reproductive organ and allows blood to fill penis tissues. The fact of cheap levitra professional the matter is that actually when you don’t engage in sexual relations in the satisfactory love making. Price and Performance Erectile dysfunction is a very common condition and a lot less scary and treatable than you may think. cialis generic canada Men who are suffering from penile problems and didn’t receive any effective result from the various treatments, should use Kamagra tablets. cipla cialis online
FILE PHOTO: An ampule of Gilead Sciences COVID-19 antiviral remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERS
Remdesivir is not available in Russia, Pharmasyntez’s director Vikram Punia said, but a generic version cannot be produced and distributed without the consent of the patent-holder, U.S. firm Gilead Sciences GILD.O.
Pharmasyntez wrote to the U.S. firm in July requesting its consent in the form of a voluntary licence, but did not hear back, Punia said.
The Siberian-based drugmaker is now asking the Kremlin to activate a compulsory licensing process on the basis of national security, granting it the right to produce the generic – labelled Remdeform – without Gilead’s consent.
“Many people’s lives could be saved using this drug. The longer this drug is inaccessible, the more people we will lose,” Punia said.
Used to monitor number of Google Analytics server requests when using Google Tag Manager
1 minute
__utmt
Used to monitor number of Google Analytics server requests
10 minutes
__utmb
Used to distinguish new sessions and visits. This cookie is set when the GA.js javascript library is loaded and there is no existing __utmb cookie. The cookie is updated every time data is sent to the Google Analytics server.
30 minutes after last activity
__utmc
Used only with old Urchin versions of Google Analytics and not with GA.js. Was used to distinguish between new sessions and visits at the end of a session.
End of session (browser)
__utmz
Contains information about the traffic source or campaign that directed user to the website. The cookie is set when the GA.js javascript is loaded and updated when data is sent to the Google Anaytics server
6 months after last activity
__utmv
Contains custom information set by the web developer via the _setCustomVar method in Google Analytics. This cookie is updated every time new data is sent to the Google Analytics server.
2 years after last activity
__utmx
Used to determine whether a user is included in an A / B or Multivariate test.
18 months
_ga
ID used to identify users
2 years
_gali
Used by Google Analytics to determine which links on a page are being clicked
30 seconds
_ga_
ID used to identify users
2 years
_gid
ID used to identify users for 24 hours after last activity
24 hours
_gac_
Contains information related to marketing campaigns of the user. These are shared with Google AdWords / Google Ads when the Google Ads and Google Analytics accounts are linked together.